Phonak Hearing Aids for Hearing Loss
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are:
Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting?
Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lab Testing
Participants are fitted with both the Phonak device and Competitor device A and undergo the AZBio Sentence Test in a simulated noisy environment.
Real-world Testing
Participants visit a local cafe with conversation partners and complete subjective questionnaires about speech clarity, ease of listening, and listening confidence.
Follow-up
Participants are monitored for any additional feedback or issues after the testing phases.
What Are the Treatments Tested in This Trial?
Interventions
- Phonak Audeo Infinio Hearing Aid
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants that are tested first with the Phonak device, and then with the Competitor device A.
Participants that are tested first with the Competitor device A, then with the Phonak device.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sonova AG
Lead Sponsor
Arnd Kaldowski
Sonova AG
Chief Executive Officer since 2018
MBA from INSEAD, MSc in Mechanical Engineering from ETH Zurich
Stefan Launer
Sonova AG
Chief Medical Officer since 2016
PhD in Natural Sciences from ETH Zurich
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.